Hosted on MSN17h
FDA beats EMA to most approved new drugs in 2024On 15 January, the two agencies released respective lists of medicines approved last year. The FDA approved 50 novel drugs ...
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025.
The FDA has accepted the BLA for lecanemab-irmb SC for weekly maintenance dosing in the treatment of early Alzheimer disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback